Hepatic sinusoidal obstruction syndrome (SOS) is an obliterative venulitis of the terminal
hepatic venules, which in its more severe forms imparts a high risk of mortality. SOS, also …

Cellular reactive oxygen species (ROS) status is stabilized by a balance of ROS generation
and elimination called redox homeostasis. ROS is increased by activation of endoplasmic …

Portal hypertension in the absence of portal vein thrombosis and without cirrhosis, but with
mild or moderate alterations of liver histology (eg, obliterative venopathy, nodular …

FOLFOX (oxaliplatin, fluorouracil and calcium folinate) is the first-line chemotherapy regimen
for colon cancer therapy in the clinic. It provides superior efficacy than oxaliplatin alone, but …

Hepatic failure is a feared complication that accounts for up to 75% of mortality after
extensive liver resection. Despite improved perioperative care, the increasing complexity …

Hepatic sinusoidal obstruction syndrome (HSOS) can be caused by the intake of
pyrrolizidine alkaloids (PAs). To date, PAs-induced HSOS has not been extensively studied …

Cancer cachexia is a multifactorial syndrome characterized by anorexia, body wasting, and
muscle and adipose tissue loss, impairing patient's tolerance to anticancer treatments and …

Sinusoidal obstruction syndrome (SOS) is characterized by damage to small hepatic vessels
affecting particularly sinusoidal endothelium. Damaged sinusoids can be associated with a …

Oxaliplatin (OXA) is a third-generation platinum anticancer drug that is mainly used for the
treatment of metastatic colorectal cancer (CRC). Of note, hepatic sinusoidal obstruction …

Purpose Oxaliplatin (OXA)-induced liver injury is one of the main limiting factors affecting the
efficacy of OXA-based chemotherapy in patients with colorectal liver metastases. In addition …